Cyto, I have no doubt that sales will increase with EVS2. The problem is the amount of increase will have to be extraordinary for this company to start earning some decent profits. I just do not see much evidence that those kind of sales gains can be expected. It looks to me like the best this company can hope for at this point is being able to cover expenses, and even that might be a couple of years away.
I am not saying it is impossible for the increase in sales necessary to make this a viable company. I just think it is a poor risk/reward based on the results we have seen so far.
News 
Market Data 
Discover 
